Sanofi: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy design ...
The Manila Times

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease. Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Bre ...

Meningitis outbreak LIVE: Uni student unable to 'see, move or speak' as fears grow

There is now a suspected case of meningitis in London following the 'devastating' outbreak in Kent which has left a ...
Wellbeing Magazine on MSN

Women’s health awareness: Understanding the CLL BTK inhibitor – 12 essential insights transforming modern treatment

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of ...